Invivyd (IVVD) Profit After Tax (2021 - 2025)
Invivyd (IVVD) posted Profit After Tax of -$11.1 million for Q4 2025, down 5.71% on a QoQ basis from -$10.5 million in Q3 2025, and up 39.98% year-over-year from -$7.9 million in Q4 2024.
Invivyd (IVVD) Profit After Tax (2021 - 2025) Analysis & Trends
Invivyd's Profit After Tax history runs 5 years deep, the most recent figure standing at -$11.1 million for Q4 2025.
- Quarterly Profit After Tax rose 39.98% year-over-year to -$11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$52.5 million (up 69.11% YoY) and the FY2025 annual result came in at -$52.5 million, up 69.09% from the prior year.
- Profit After Tax was -$11.1 million for Q4 2025 at Invivyd, down from -$10.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$10.5 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
- A 5-year average of -$44.5 million and a median of -$44.8 million in 2021 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 160.12% — and 2025, when it surged 82.76%.
- Invivyd's Profit After Tax stood at -$83.0 million in 2021, then jumped by 46.01% to -$44.8 million in 2022, then sank by 64.27% to -$73.7 million in 2023, then jumped by 74.96% to -$18.4 million in 2024, then soared by 39.98% to -$11.1 million in 2025.
- Business Quant data shows IVVD's Profit After Tax at -$11.1 million in Q4 2025, -$10.5 million in Q3 2025, and -$14.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | -65.60 Mn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | -26.94 Mn |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 482.00 Mn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | -453.82 Mn |
| 10 | Invivyd | 102.33 Mn | -124.36 Mn | 16.07 Mn | -11.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.07 Mn |
| Sep 30, 2025 | -10.47 Mn |
| Jun 30, 2025 | -14.66 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Dec 31, 2024 | -18.44 Mn |
| Sep 30, 2024 | -60.75 Mn |
| Jun 30, 2024 | -47.25 Mn |
| Mar 31, 2024 | -43.50 Mn |
| Dec 31, 2023 | -73.65 Mn |
| Sep 30, 2023 | -39.44 Mn |
| Jun 30, 2023 | -50.23 Mn |
| Mar 31, 2023 | -35.32 Mn |
| Dec 31, 2022 | -44.84 Mn |
| Sep 30, 2022 | -45.04 Mn |
| Jun 30, 2022 | -50.99 Mn |
| Mar 31, 2022 | -100.67 Mn |
| Dec 31, 2021 | -83.04 Mn |
| Sep 30, 2021 | -60.38 Mn |
| Jun 30, 2021 | -44.67 Mn |
| Mar 31, 2021 | -38.70 Mn |